In particular, there is the TATEN trial (NCT04251169), investigating pembrolizumab plus paclitaxel in HR+/HER2− non-luminal (by PAM50) advanced BC after CDK4/6is progression, and a phase I study (NCT04134884) to test the safety of a combination of ASTX727 with talazoparib in patients with triple-negative BC or HER2− mBC [149,150]. Here, ERBB2 is linked to breast cancer.